Aniracetam
A racetam-class cognitive enhancer that's prescription-only in parts of Europe and sold as a 'nootropic supplement' (in legally grey territory) in the US. Several small 20+ year-old European RCTs support modest cognitive benefit in older adults with memory impairment or post-stroke aphasia. There's essentially no good evidence in healthy adults.
Research compound — not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only — talk to a clinician before considering it.
Quick decision guide
May help most
Adults with documented age-related cognitive impairment who have discussed unconventional options with a neurologist — not a general 'study aid'.
Common dosing range
1000–1500 mg/day, split into 2–3 doses, taken with food containing some fat.
When to expect effects
Weeks for cognition in trial populations; acute mood/focus effects (if any) within an hour but short-lived.
Watch out for
Not an FDA-approved supplement or drug in the US. Product purity, dose accuracy, and long-term safety are not well characterised.
Evidence snapshot
What is it
Aniracetam is a synthetic compound in the racetam family of cognitive-enhancing drugs (nootropics). It is a prescription medication in some European countries for cognitive impairment and dementia, but is unregulated and sold as a research chemical or supplement in the United States, where it does not meet criteria as a dietary supplement ingredient.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Age-associated memory impairment Limited Evidence | Statistically significant improvement on cognitive batteries vs placebo at 1500 mg/day over 60 days; clinical magnitude modest | Older adults with mild age-related cognitive decline, under clinical supervision | 4–8 weeks in the published trials |
Post-stroke aphasia and cerebrovascular cognitive impairment Limited Evidence | Modest improvement on aphasia and cognition scales in small short-duration trials | Post-stroke patients with persistent cognitive deficits, in a research or specialist context | 4–12 weeks in the published trials |
Anxiety, mood, and social functioning Mixed Evidence | Not quantified in modern human anxiety RCTs | Not established in humans | Not characterised in humans |
Cognitive enhancement in healthy adults Mixed Evidence | No reliable human evidence | No identified population | Not established |
Age-associated memory impairment
- Effect
- Statistically significant improvement on cognitive batteries vs placebo at 1500 mg/day over 60 days; clinical magnitude modest
- Best fit
- Older adults with mild age-related cognitive decline, under clinical supervision
- Time
- 4–8 weeks in the published trials
Post-stroke aphasia and cerebrovascular cognitive impairment
- Effect
- Modest improvement on aphasia and cognition scales in small short-duration trials
- Best fit
- Post-stroke patients with persistent cognitive deficits, in a research or specialist context
- Time
- 4–12 weeks in the published trials
Anxiety, mood, and social functioning
- Effect
- Not quantified in modern human anxiety RCTs
- Best fit
- Not established in humans
- Time
- Not characterised in humans
Cognitive enhancement in healthy adults
- Effect
- No reliable human evidence
- Best fit
- No identified population
- Time
- Not established
Evidence for 4 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Age-associated memory impairment
Disease adjunctA 1991 60-day Italian multicentre RCT of 109 patients with age-associated memory impairment found aniracetam 1500 mg/day significantly improved cognitive performance and depressive symptom scores vs placebo, with no difference in adverse events. Earlier 1980s European trials in senile cognitive disorders and Alzheimer-type dementia reported similar small-to-moderate benefits at 1500 mg/day. The trials are old, small, and have not been replicated in modern protocols.
Bottom line: Modest, dated evidence for impaired cognition in older adults — not a substitute for a proper dementia work-up.
Evidence is mixed
Most positive trials are 20–35 years old, small, and conducted in Italy or other European centres where aniracetam was on-patent and prescription-only. Modern replication is essentially absent.
Post-stroke aphasia and cerebrovascular cognitive impairment
Disease adjunctSeveral small European trials in the 1990s reported aniracetam 1500 mg/day improved aphasia scores and global cognition in post-stroke patients vs placebo. The Lee & Benfield 1994 narrative review summarises this literature. Sample sizes are small (typically <100 patients), follow-up short (4–12 weeks), and the trials have not been pooled in a modern systematic review.
Bottom line: Historical European trials are positive but small and dated. Standard stroke rehab remains the evidence-based path.
Anxiety, mood, and social functioning
Mechanism onlyAniracetam is the racetam most often associated with anxiolytic and mood-lifting effects, but the supporting data are almost entirely rodent studies (social interaction, elevated plus-maze, scopolamine reversal). Human RCT evidence specifically for anxiety or mood — separate from the 'depressive symptoms' subscale moves in the cognitive-impairment trials — is essentially absent.
Bottom line: Strong rodent signal, no real human anxiety trials. Don't substitute for evidence-based anxiety care.
Cognitive enhancement in healthy adults
Mechanism onlyDespite a large 'nootropic stack' marketing scene, there are no high-quality RCTs of aniracetam improving memory, attention, or executive function in healthy adults. The rationale is mechanistic — AMPA receptor positive allosteric modulation — but human translation is unproven and the subjective effect, if any, is described as subtle.
Bottom line: The 'study drug' use case is unsupported by clinical evidence.
How it works
How to take it
What to track
Bottom line: If you're going to try aniracetam, mirror the trial dosing (1000–1500 mg/day with food, split 2–3 times), keep a journal, and revisit at 8 weeks. It's not a US-approved drug or supplement — discuss with a clinician.
4 commercial forms
Compare the main delivery options and what they’re best suited for.
Aniracetam capsules (typical 750 mg)
Trial-relevant doseThe most practical form. Matches the per-dose size used in much of the European clinical literature when taken 2× day. Avoid air and light exposure after opening.
Lipophilic; absorption better with a fatty meal.
Aniracetam bulk powder
Hard to doseCheaper per gram but extremely bitter, hygroscopic, and difficult to weigh accurately at 750 mg with a kitchen scale. Strong recommendation to use only with an analytical-grade scale and pre-divided capsules.
Same as capsules; risk is dose-measurement error.
Combination 'nootropic stacks' with choline
ConvenienceOften bundled with alpha-GPC or CDP-choline on the rationale that aniracetam-induced headache may reflect relative choline shortfall. Convenient but obscures whether benefit/side-effects come from aniracetam or the choline.
No formal pharmacokinetic interaction studied.
Other racetams (for comparison)
Sibling compoundsPiracetam (the prototype), oxiracetam (more 'stimulating' subjectively, no anxiolytic signal), pramiracetam (much higher potency, less mood data), phenylpiracetam (banned in sport, more stimulant-like). None has high-quality healthy-adult RCT support either.
Each has its own pharmacokinetics; not interchangeable mg-for-mg.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Aniracetam is not FDA-approved in the US either as a drug or as a dietary supplement. Consumer products are not subject to GMP enforcement; identity, purity, and dose accuracy are unverified.
Long-term safety beyond 12 weeks is not established. Chronic use of any AMPA modulator could theoretically affect glutamate signalling; we have no human data to reassure on this point.
Headache is the most consistent side effect across the racetam class and often responds to a choline source (CDP-choline / alpha-GPC), suggesting some users may be marginally choline-deficient on aniracetam.
Who should avoid it
- Anyone under 18, pregnant, breastfeeding, or trying to conceive — no safety data.
- People taking SSRIs, MAOIs, anticoagulants, or any CNS-active prescription — interactions are poorly characterised.
- People with significant liver or kidney impairment — aniracetam is metabolised in the liver to several active metabolites and cleared renally.
- People with a history of psychosis, bipolar disorder, or severe anxiety — the racetam class can occasionally precipitate or worsen these states.
Pregnancy & breastfeeding
Avoid in pregnancy and while breastfeeding. There are no human safety data for aniracetam during pregnancy and it crosses the blood-brain barrier; teratogenicity has not been studied to a reassuring standard.
Bottom line: Approach aniracetam as an off-label foreign prescription drug, not a casual supplement. Headache, anxiety, and unknown long-term effects are the realistic risks; product-quality risk is also non-trivial in the US market.
Interactions
Aniracetam's pro-cognitive effect depends partly on cholinergic transmission; anticholinergics may blunt the benefit and contribute to confusion in older users.
Limited data — aniracetam affects serotonergic and noradrenergic systems in animal studies, and combination effects in humans haven't been formally studied.
Some racetams (especially piracetam) affect platelet aggregation; aniracetam shares structural features and the same caution is usually applied even though aniracetam-specific human data are sparse.
Common nootropic-stack combination. Can amplify anxiety, jitteriness, and insomnia if doses are not staggered.
Aniracetam interacts with GABAergic and glutamatergic systems; combined effects with alcohol are not well-characterised in humans. Avoid combining heavily.
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is aniracetam legal?⌄
It varies by country. In some European countries it is a prescription medication. In the US, the FDA does not recognize it as a dietary supplement ingredient, so its sale as a supplement is technically not permitted, though it is widely available online.
Does aniracetam actually improve memory?⌄
Evidence for cognitive enhancement in healthy people is weak. Most clinical studies are in elderly patients with cognitive impairment, where modest benefits have been reported.
Why take choline with aniracetam?⌄
Aniracetam may increase acetylcholine demand. Co-supplementing with choline sources like alpha-GPC or CDP-choline is widely reported to reduce racetam-related headaches.
How does aniracetam differ from piracetam?⌄
Aniracetam is fat-soluble (piracetam is water-soluble), has a shorter half-life, and is generally considered to have stronger anxiolytic effects and weaker memory effects than piracetam.
Are there long-term risks?⌄
Long-term safety data are limited, especially in healthy users. Caution and periodic breaks are reasonable for chronic use.
References by claim
Age-associated memory impairment
Anxiety, mood, and social functioning
Bartolini et al., 1996 — Pharmacology Biochemistry and Behavior (1996) link
Track Aniracetam with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research — much of it preclinical or early-stage — not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.